Safety and Tolerability of Single and Multiple Doses of LB-102 in Healthy Adults
Status:
Completed
Trial end date:
2020-11-09
Target enrollment:
Participant gender:
Summary
A Single Ascending Dose (SAD; Part A) and Multiple Ascending Dose (MAD; Part B) Phase 1 Study
of LB-102 N-Methyl amisulpride) in healthy volunteers. The primary objective is to evaluate
the safety and the tolerability of a single oral dose (SAD) and multiple oral doses (MAD) of
LB-102 as compared to placebo. The secondary objectives are to evaluate the pharmacokinetics
(PK) and pharmacodynamics (PD) of LB-102.